New cancer drug enters human testing
NCT ID NCT07110584
Summary
This early-stage study is testing an experimental drug called MDX2004 in people with advanced cancers that have spread or cannot be removed by surgery. The main goals are to find a safe dose, check for side effects, and see if the drug can shrink tumors. It will enroll about 235 adults with various types of solid tumors to gather this initial information.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Calvary Mater Newcastle
RECRUITINGWaratah, New South Wales, 2298, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hadassah University Hospital-Ein Kerem
RECRUITINGJerusalem, 9574409, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Liverpool Hospital
RECRUITINGLiverpool, New South Wales, 2170, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Princess Alexandra Hospital
RECRUITINGWoolloongabba, Queensland, 4102, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rambam Health Care Campus
RECRUITINGHaifa, 3109601, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Tel Aviv Sourasky Medical Center
RECRUITINGTel Aviv, 6423906, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.